INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics

INmune Bio Inc. - Common stock (INMB): $11.75

0.12 (+1.03%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add INMB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#356 of 365

in industry

INMB Price/Volume Stats

Current price $11.75 52-week high $14.74
Prev. close $11.63 52-week low $5.87
Day low $11.28 Volume 96,400
Day high $12.05 Avg. volume 78,741
50-day MA $12.07 Dividend yield N/A
200-day MA $9.52 Market Cap 211.76M

INMB Stock Price Chart Interactive Chart >

INMB POWR Grades

  • INMB scores best on the Quality dimension, with a Quality rank ahead of 33.44% of US stocks.
  • INMB's strongest trending metric is Value; it's been moving down over the last 26 weeks.
  • INMB's current lowest rank is in the Value metric (where it is better than 11.24% of US stocks).

INMB Stock Summary

  • INMUNE BIO INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 8.89% of US listed stocks.
  • INMB's price/sales ratio is 897.06; that's higher than the P/S ratio of 99.33% of US stocks.
  • As for revenue growth, note that INMB's revenue has grown -49.09% over the past 12 months; that beats the revenue growth of merely 4.74% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INMUNE BIO INC are LIPO, MRTX, ABCL, MTNB, and RGTI.
  • Visit INMB's SEC page to see the company's official filings. To visit the company's web site, go to www.inmunebio.com.

INMB Valuation Summary

  • In comparison to the median Healthcare stock, INMB's price/earnings ratio is 125.39% lower, now standing at -7.4.
  • Over the past 60 months, INMB's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for INMB.

Stock Date P/S P/B P/E EV/EBIT
INMB 2023-12-29 905.8 4.6 -7.4 -6.3
INMB 2023-12-28 921.0 4.7 -7.5 -6.5
INMB 2023-12-27 902.7 4.6 -7.4 -6.3
INMB 2023-12-26 868.7 4.4 -7.1 -6.0
INMB 2023-12-22 846.4 4.3 -6.9 -5.9
INMB 2023-12-21 828.6 4.2 -6.8 -5.7

INMB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INMB has a Quality Grade of D, ranking ahead of 11.03% of graded US stocks.
  • INMB's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows INMB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 1 -3.952
2021-03-31 0 1 -15.163
2020-12-31 0 1 -22.264
2020-09-30 0 NA -21.947
2020-06-30 0 NA -15.048
2020-03-31 0 NA -9.777

INMB Price Target

For more insight on analysts targets of INMB, see our INMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.75 Average Broker Recommendation 1.38 (Strong Buy)

INmune Bio Inc. - Common stock (INMB) Company Bio


INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.


INMB Latest News Stream


Event/Time News Detail
Loading, please wait...

INMB Latest Social Stream


Loading social stream, please wait...

View Full INMB Social Stream

Latest INMB News From Around the Web

Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!

William White on InvestorPlace | December 19, 2023

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023. Boca R

Yahoo | December 18, 2023

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the tumor killing immunology of the tumor microenvironment. Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is prese

Yahoo | November 29, 2023

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spa

Yahoo | November 27, 2023

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Yahoo | November 17, 2023

Read More 'INMB' Stories Here

INMB Price Returns

1-mo -0.59%
3-mo 4.35%
6-mo 73.56%
1-year 95.51%
3-year -1.34%
5-year 49.68%
YTD 4.35%
2023 77.60%
2022 -37.84%
2021 -40.77%
2020 196.90%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!